Anemia of Renal Disease

ByGloria F. Gerber, MD, Johns Hopkins School of Medicine, Division of Hematology
Reviewed/Revised Jun 2023
View Patient Education

Anemia of renal disease is a hypoproliferative anemia resulting primarily from deficient erythropoietin (EPO) or a diminished response to it; it tends to be normocytic and normochromic. Treatment includes measures to correct the underlying disorder and supplementation with EPO and sometimes iron.

(See also Overview of Decreased Erythropoiesis.)

Anemia in chronic renal disease is multifactorial.

The most common mechanism is

  • Hypoproliferation due to decreased erythropoietin (EPO) production

Lack of EPO leads to loss of erythroferrone production, causing loss of hepcidin suppression and increased iron sequestration (as observed in the anemia of chronic disease1).

Other factors include

  • Blood loss due to dysfunctional platelets, dialysis, and/or angiodysplasia

  • Bone marrow resistance to EPO

  • Secondary hyperparathyroidism

  • Uremia (leading to shortened red blood cell [RBC] survival)

The deficiency in renal production of EPO and the severity of anemia do not always correlate with the extent of renal dysfunction; anemia occurs when creatinine clearance is < 45 mL/minute (< 0.75 mL/s/m2). Renal glomerular lesions (eg, due to amyloidosis, diabetic nephropathy) generally result in the most severe anemia for their degree of renal excretory failure.

General reference

  1. 1. Kautz L, Jung G, Valore EV, et al: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46:678–684, 2014. doi: 10.1038/ng.2996

Diagnosis of Anemia of Renal Disease

  • Complete blood count (CBC), reticulocyte count, and peripheral smear

Diagnosis of anemia of renal disease is based on demonstration of renal insufficiency, normocytic anemia, and peripheral reticulocytopenia.

The bone marrow may show erythroid hypoplasia. RBC fragmentation identified on the peripheral smear, particularly if there is thrombocytopenia, suggests microangiopathic hemolytic anemia and warrants additional investigation and treatment.

Treatment of Anemia of Renal Disease

  • Treatment of underlying renal disease

  • Sometimes, recombinant erythropoietin and iron supplements

Treatment of anemia of renal disease is directed at

  • Improving renal function

  • Increasing RBC production

If renal function returns to normal, anemia is slowly corrected.

venous thromboembolism, myocardial infarction, death) may occur when hemoglobin rises to > 12 to 13 g/dL (> 120 to 130 g/L). Lower doses of EPO are used in patients with chronic kidney disease who are not on dialysis.

In addition, adequate repletion of iron stores is required to ensure an adequate response to recombinant EPO, and concurrent iron supplementation is often needed. The addition of IV iron is considered in patients with hemoglobin < 10 g/dL (< 100 g/L), ferritin ≤ 500 ng/mL (< 500 micrograms/L), and transferrin saturation (TSAT) ≤ 30%.

In almost all cases, maximum increases in RBCs are reached by 8 to 12 weeks.

1); however, long-term safety data are lacking.

Treatment reference

  1. 1. Singh AK, Carroll K, Perkovic V, et al: Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med 2021;385(25):2325-2335. doi:10.1056/NEJMoa2113379

Drugs Mentioned In This Article
quizzes_lightbulb_red
Test your KnowledgeTake a Quiz!
Download the free Merck Manual App iOS ANDROID
Download the free Merck Manual App iOS ANDROID
Download the free Merck Manual App iOS ANDROID